Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group

Bartolomeo, Maria Di; Bajetta, Emilio; Buzzoni, Roberto; Mariani, Luigi; Carnaghi, Carlo; Somma, L.; Zilembo, Nicoletta; Leo, Angelo Di

doi:10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4

Cited by 262 publications

(106 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six studies in the following decade showed that 15%-86% of patients with advanced NETs achieved stable disease with octreotide SC (Table 1) [22,23,26,28,29,31]. After the introduction of octreotide LAR, several more studies reinforced the results observed with the SC formulation [27, 30, 32, 34 -37].…”

Section: Octreotidesupporting

confidence: 74%

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

2012

View full text Add to dashboard Cite

Background. For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect antitumor effects in secretory and nonsecretory NETs in addition to symptom control in secretory NETs.Methods. A systematic review of MEDLINE was conducted to identify studies that investigated the antitumor effects of octreotide or lanreotide for patients with NETs. Additional studies not published in the peer-reviewed literature were identified by searching online abstracts.Results. In all, 17 octreotide trials and 11 lanreotide trials that included antitumor effects were identified. Partial response rates were between 0% and 31%, and stable disease

show abstract

Section: Octreotidesupporting

confidence: 74%

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

2012

View full text Add to dashboard Cite

show abstract

“…A long-acting depot form of octreotide (octreotide LAR), which can be administered on a monthly basis, has gained popularity. Octreotide therapy results in remission or stabilization of tumor markers, such as serotonin and chromogranin A, in approximately 60% to 70% of patients [27,28].…”

Section: Somatostatin Analogssupporting

confidence: 88%

Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment

Kang¹,

Ryu²,

Lee³

et al. 2017

Korean J Pancreas Biliary Tract

View full text Add to dashboard Cite

Well-to-moderately differentiated neuroendocrine tumors of gastroesophageal and pancreatic origin (GEP-NETs) with liver metastasis are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. Surgical resection of hepatic metastases or hepatic artery embolization may be beneficial in patients with hepatic-predominant metastatic disease. Patients with "carcinoid" syndrome and syndromes associated with functional pancreatic NET (PNET) can be effectively treated with somatostatin analogs. On the other hand, the efficacy of systemic chemotherapy for these patients is limited. A placebo-controlled, double-blind, prospective, and randomized study showed that octreotide LAR improves progression-free survival in patients with advanced midgut functional "carcinoids." In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR inhibitor everolimus is associated with improved progression-free survival. Based on these studies, octreotide LAR, sunitinib, or everolimus are now considered as first-line therapeutic options in patients with advanced NET. Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis.

show abstract

“…By contrast, SSTR4 up-regulates the MAPK/ERK1/2 pathway leading to proliferative activity. SSTRs are also related to multiple secondary effectors such as adenylyl cyclase and protein kinase A (6) and ion channel regulation such as K C channel, voltagedependent Ca 2C channel, Na C /H C exchanger or AMPA/ Kainate glutamate channels (7) (Fig. 2).…”

Section: Molecular Biology and The Rationale Behind The Use Of Ssas Amentioning

confidence: 99%

GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours

Alonso‐Gordoa

Capdevila

Grande

2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) represent a less frequent and heterogeneous group of tumours, which has experienced, in recent years, a significant increase in effective therapeutic possibilities overcoming the disappointing results from chemotherapy. Initial improvements in treatment strategies came from somatostatin analogues (SSAs) that have widely demonstrated a significant improvement in symptomatic relief and tumour control growth by a complex mechanism of action over cell survival, angiogenesis and immunomodulation. Recent investigations have pointed out novel SSAs with a wider binding profile (pasireotide), chimeric molecules against somatostatin receptors and dopamine receptors and the combination with targeted agents, such as mTOR inhibitors or antiangiogenic agents. Immunotherapy is the second cornerstone in NET treatment and has been represented with interferon alpha for a long time, with a demonstrated activity on tumour and clinical response. Its less manageable adverse events have limited its usage. However, different checkpoints in immune system regulation have been effectively targeted in different solid tumours, and novel approaches are currently arising in NETs. In conclusion, biotherapy remains an active treatment strategy for initial approach in patients with NETs. Further investigation on patients' selection, molecular profiles, treatment sequence or combination and optimisation of current and novel biotherapy agents is required.

show abstract

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group

Cited by 262 publications

References 23 publications

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment

GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours

Contact Info

Product

Resources

About